Navigation Links
Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
Date:12/31/2013

herapeutic molecules or gene delivery systems, Intrexon is equipped to pursue several different therapeutic approaches for treating the complexities associated with FRDA. 

"As an inventor and integrator of technology platforms, we will make use of our UltraVector® multi-gene engineering, RTS® gene switch, advanced Protein Engineering, and other platforms to develop therapeutic candidates designed to treat both the neurological and the cardiovascular pathologies of FRDA.  We are confident that our ability to pursue multiple approaches for treating this complex disease will significantly increase our probability of success."

About Agilis Biotherapeutics, LLC
Agilis Biotherapeutics, LLC, is a biotechnology company focused on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are no or limited treatment options. We believe that engineered DNA-based therapeutics provide the ability to target underlying disease mechanisms with tightly-controlled multigenic modalities leading to "functional cures" for patients with these diseases.

We invite you to visit Agilis at www.agilisbio.com.  

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy and the Environment to create biologically-based products that improve the quality of life and the health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems.  The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells.  We call our
'/>"/>

SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
2. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
3. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
4. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
5. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
6. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
9. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
10. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
11. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, 2015 ... that Roger Jeffs , Ph.D., President and Co-Chief Executive ... on the company,s business at the Deutsche Bank 40 th ... . The presentation will take place on ... can be accessed via a live webcast on the United ...
(Date:4/30/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, announced plans to ... 2015 on May 7, 2015 after the close of ... host a conference call at 4:30 p.m. Eastern Time ... financial results. During the conference call, material information concerning ...
(Date:4/30/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) reported total ... were $4.4 million, compared to $8.0 million during the same ... quarter was $8.9 million, or $0.23 per basic and diluted ... same period in 2014, of $8.7 million, or $0.27 per ... cash, cash equivalents and investments totaled $117.5 million. , ...
(Date:4/30/2015)... April 30, 2015 Nitto Avecia, ... announces its increased capacity and production capability to ... client variety and service fulfillment continues to drive ... improve process throughput capacities. , In ... installed downstream process equipment at its Milford, MA ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... Intercell AG (VSE: ICLL) today announced that it ... U.S. Food and Drug Administration,s (FDA) approval of IXIARO(R), ... (JE). The initial target for use of Intercell,s vaccine ... U.S. market - will be adult travelers and military ...
... DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or ... financial results for 2008. DOR,s revenues for 2008 were ... The increase was due primarily to progress with ... of certain research and development milestones with our subcontractors. ...
... Va., March 31 - Innocoll, Inc. announced that its ... application for its CollaRx(TM) Lidocaine Sponge for the management ... year 13 million patients worldwide suffer from chronic wounds ... 35 percent of all chronic wounds do not ...
Cached Biology Technology:Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 2Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 5Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge 2
(Date:4/1/2015)... 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces the second ... is underway to early access pre-order customers. ... at retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, ... was accepted at all outlets and very easy to ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... Institute and MIT have engineered yeast that can improve ... component to making biofuels a significant part of the ... additive to improve gasoline combustibility, ethanol is often touted ... crisis. But there are significant obstacles to producing ethanol. ...
... manipulate the brain's perception of jaw movement while words ... importance of non-auditory sensory cues in the brain's control ... and David Ostry of McGill University and appear in ... published by Cell Press. , When we speak, ...
... Institute have identified a novel biomarker for brain tumors ... play when the tumor spreads or comes back after ... cerebrospinal fluid of patients with malignant astrocytoma and mediates ... of Clinical Cancer Research. , The biomarker, ...
Cached Biology News:Engineered yeast speeds ethanol production 2Sensory feedback during speech: The brain attunes to more than just sound 2Newly identified biomarker detects and regulates spread of brain tumors 2
... The new MALDI O-TOF creates a ... on an orthogonal platform that has been ... the University of Manitoba. , As the ... orthogonal design and collisional cooling, the prOTOF ...
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
37-1A9...
Biology Products: